A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Active:	Yes
Cancer Type:	Solid Tumor Unknown Primary	NCT ID:	NCT05581004
Trial Phases:	Phase I	Protocol IDs:	GO43860 (primary) NCI-2022-08852 2021-006708-34
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Genentech Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT05581004

Summary

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics
(PK), and anti-tumor activity of RO7502175 when administered as a single agent and in
combination with atezolizumab or pembrolizumab in adult participants with locally
advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head
and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC),
esophageal cancer, gastric cancer, cervical cancer, colorectal cancer (CRC), urothelial
carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC).
Participants will be enrolled in 2 stages: dose escalation and dose expansion.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.